Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial

Xinxin Wang, Canrong Lu, Bo Wei, Shuo Li, Ziyu Li, Yingwei Xue, Yingjiang Ye, Zhongtao Zhang, Yihong Sun, Liang Han, Kwok Yan Li, Linghua Zhu, Zhichao Zheng, Yanbing Zhou, Yulong He, Fei Li, Pin Liang, Hua Huang, Guoli Li, Xian Shen, Jiafu Ji, Yun Tang, Zekuan Xu, Lin Chen, on behalf of Resonance study groupJournal of Hematology & Oncology 2024 · DOI · OpenAlex

Abstract

The phase 3 RESONANCE trial investigated the efficacy and safety of perioperative versus adjuvant S-1 plus oxaliplatin (SOX) chemotherapy for stage II/III resectable gastric cancer. In this randomized, open-label trial involving 756 patients in the modified intention-to-treat (mITT) population, perioperative chemotherapy (PC) significantly improved the three-year disease-free survival (DFS) rate (61.7% vs. 53.8%, p = 0.019) and the R0 resection rate (94.9% vs. 83.7%, p < 0.0001) compared to adjuvant chemotherapy (AC). Safety profiles were comparable between the two groups. These findings suggest that perioperative SOX is a superior approach for managing locally advanced gastric cancer.

Introduction

Treatment standards for locally advanced gastric cancer have historically differed by region. While Western guidelines favor perioperative chemotherapy, East Asian practice has traditionally centered on upfront surgery followed by adjuvant chemotherapy. The RESONANCE trial aimed to provide robust evidence for the use of perioperative SOX (S-1 plus oxaliplatin) in an Asian population, comparing it directly against the standard adjuvant approach.

Methods

This phase 3 trial enrolled 772 patients with stage II/III resectable gastric cancer across 19 centers in China. Patients were randomized to either:

  1. Perioperative Chemotherapy (PC): 2–4 cycles of SOX before surgery, followed by 4–6 cycles after surgery.
  2. Adjuvant Chemotherapy (AC): Upfront surgery followed by 8 cycles of SOX.

The primary endpoint was the three-year DFS rate in the mITT population (n=756).

Results

The trial met its primary endpoint, demonstrating a significant survival advantage for the perioperative approach. The three-year DFS rate was 61.7% in the PC arm compared to 53.8% in the AC arm (HR 0.76; 95% CI 0.61-0.96; p=0.019).

Disease-free survival (DFS) analysis for the total mITT population (a), Stage II patients (b), and Stage III patients (c).

Subgroup analysis revealed that the benefit was most pronounced in patients with Stage III disease (HR 0.72, p=0.009), whereas the difference in Stage II patients did not reach statistical significance (p=0.272).

Beyond survival, the PC arm showed superior surgical outcomes. The R0 resection rate—indicating complete tumor removal with clear margins—was significantly higher in the PC group (94.9% vs. 83.7%, p < 0.0001). Additionally, 23.6% of patients in the PC arm achieved a pathological complete response (pCR), indicating the effectiveness of preoperative "downstaging."

Patient compliance was also notably higher in the perioperative group; 41.1% of PC patients completed all eight cycles of chemotherapy, compared to only 19.2% in the AC group. This suggests that chemotherapy is better tolerated when initiated before the physiological stress of major surgery.

Discussion and Conclusion

The RESONANCE trial provides strong evidence that perioperative SOX chemotherapy improves survival and surgical success for stage II/III gastric cancer. The "downstaging" effect of preoperative treatment likely facilitates more effective R0 resections. Furthermore, the improved compliance in the PC arm highlights a practical advantage of the perioperative sequence.

While the study is limited by potential staging inaccuracies and a lack of molecular biomarker data (e.g., MSI status), the results support a shift toward perioperative SOX as a standard of care for locally advanced gastric cancer in Asian clinical practice. Future research will likely explore the integration of immunotherapy into this perioperative framework.

Summary updated

Abstract

Evidence from Europe shows that perioperative chemotherapy may be beneficial for the treatment of locally advanced gastric cancer, but reliable and robust data is lacking. To rectify this, the phase 3 RESONANCE trial investigated the efficacy and safety of S-1 plus oxaliplatin (SOX) as a perioperative chemotherapy regimen for gastric cancer. This randomized, open-label trial enrolled patients from 19 medical centers with stage II/III resectable gastric cancer who were centrally randomly assigned to either perioperative chemotherapy (PC) arm or adjuvant chemotherapy (AC) arm. Patients in the PC arm received two to four cycles of SOX followed by surgery and four to six cycles of SOX. Patients in the AC arm received upfront surgery and eight cycles of SOX. 386 patients in each group were enrolled and 756 (382 in PC and 374 in AC) were included in the mITT population. The three-year DFS rate was 61.7% in the PC arm and 53.8% in the AC arm (log-rank p = 0.019). The R0 resection rate in the PC arm was significantly higher than that in the AC arm (94.9% vs. 83.7%, p < 0.0001). There was no difference between two arms in surgical outcomes or postoperative complications. Safety-related data were like the known safety profile. In conclusion, from a clinical perspective, this trial indicated a trend towards higher three-year disease-free survival rate with perioperative SOX in stage II/III resectable gastric cancer with well-tolerated toxicity compared to adjuvant SOX, which might provide a theoretical basis for applying perioperative SOX in advanced gastric cancer patients. (ClinicalTrials.gov NCT01583361).
BibTeX
@article{wang2024perioperative,
  author = {Xinxin Wang and Canrong Lu and Bo Wei and Shuo Li and Ziyu Li and Yingwei Xue and Yingjiang Ye and Zhongtao Zhang and Yihong Sun and Liang Han and Kwok Yan Li and Linghua Zhu and Zhichao Zheng and Yanbing Zhou and Yulong He and Fei Li and Xin Wang and Pin Liang and Hua Huang and Guoli Li and Xian Shen and Jiafu Ji and Yun Tang and Zekuan Xu and Lin Chen and on behalf of RESONANCE study group},
  title = {{Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial}},
  journal = {Journal of Hematology \& Oncology},
  year = {2024},
  doi = {10.1186/s13045-024-01536-7},
}
Figure